Drug Discovery

Today we are joined by Ivan Kairatov, a biopharma expert with deep insights into the intersection of technology and medical innovation. For decades, the goal of HIV treatment has been management—using antiretroviral therapy to suppress the virus to undetectable levels. A true cure has remained

Beyond the primary battle against tumors, many cancer patients face a debilitating secondary war against cachexia, a profound wasting syndrome that silently erodes the body and spirit. This severe metabolic condition, marked by unintentional weight loss and muscle deterioration, significantly

In the high-stakes world of biopharmaceutical development, the line between a groundbreaking success and a costly failure is often defined by the unforgiving logic of statistical significance, a reality Nektar Therapeutics recently confronted with its autoimmune drug, rezpegaldesleukin. The company

The intricate dance of cellular machinery required to produce life-saving biologic therapies has long been dictated by a rhythm of chance, but a new era of genomic precision is fundamentally changing the tempo of drug development. For decades, the biopharmaceutical industry has grappled with a

The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further

The translation of profound academic research into tangible technologies that address humanity's most pressing challenges stands as a hallmark of institutional excellence, a commitment exemplified by the University of California, Los Angeles. In a significant recognition of this mission, two